carmustine has been researched along with Cancer of Colon in 74 studies
Carmustine: A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed)
carmustine : A member of the class of N-nitrosoureas that is 1,3-bis(2-chloroethyl)urea in which one of the nitrogens is substituted by a nitroso group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The ability of lonidamine (LND), an energolytic derivative of indazole carboxylic acid, to modulate the cytotoxic activity of mitomycin C (MMC) and 1,3,bis(2-chloroethyl)-1-nitrosourea (BCNU) was investigated in two human adenocarcinoma cell lines (LoVo and HT29) expressing different sensitivity profiles to the drugs." | 7.69 | In vitro effect of lonidamine on the cytotoxicity of mitomycin C and BCNU in human colon adenocarcinoma cells. ( Bearzatto, A; Costa, A; Orlandi, L; Silvestrini, R; Villa, R; Zaffaroni, N, 1994) |
| "The ability of lonidamine (LND), an energolytic derivative of indazole carboxylic acid, to modulate the cytotoxic activity of mitomycin C (MMC) and 1,3,bis(2-chloroethyl)-1-nitrosourea (BCNU) was investigated in two human adenocarcinoma cell lines (LoVo and HT29) expressing different sensitivity profiles to the drugs." | 3.69 | In vitro effect of lonidamine on the cytotoxicity of mitomycin C and BCNU in human colon adenocarcinoma cells. ( Bearzatto, A; Costa, A; Orlandi, L; Silvestrini, R; Villa, R; Zaffaroni, N, 1994) |
| " The chemotherapeutic agents 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), carboplatin, and camptothecin were incorporated into controlled-release polymers and tested individually against intracranial challenges with one of four tumors (lung carcinoma, renal cell carcinoma, colon carcinoma, and melanoma)." | 3.69 | Local delivery of chemotherapy and concurrent external beam radiotherapy prolongs survival in metastatic brain tumor models. ( Anderson, RC; Babel, KM; Brat, DJ; Brem, H; Ewend, MG; Pinn, ML; Tabassi, K; Tyler, BM; Williams, JA, 1996) |
| "In small cell lung cancer initial high dose therapy followed by non-cross-resistant regimens may prove effective." | 2.37 | High dose chemotherapy in solid tumours in adults. ( Peters, W; Souhami, R, 1986) |
| "We used two human colon cancer cell lines, the HT29 and SW620 which harbor the R273H DNA contact abrogatory mutation in p53." | 1.43 | Piperlongumine exerts cytotoxic effects against cancer cells with mutant p53 proteins at least in part by restoring the biological functions of the tumor suppressor. ( Basak, D; Punganuru, SR; Srivenugopal, KS, 2016) |
| "Following treatment of three colon cancer cell lines, HCT116, SW480, and VACO-8, for 48 h with 0." | 1.30 | Increased sensitivity of human colon cancer cells to DNA cross-linking agents after GRP78 up-regulation. ( Belfi, CA; Berger, NA; Berger, SJ; Chatterjee, S; Gosky, DM, 1999) |
| "10 patients with advanced colorectal cancer were treated with elevated doses of carmustine and mitomycin C." | 1.29 | Elevated doses of carmustine and mitomycin C, with lonidamine enhancement and autologous bone marrow transplantation in the treatment of advanced colorectal cancer: results from a pilot study. ( Codacci Pisanelli, G; Franchi, F; Giovagnorio, F; Gualdi, G; Guazzugli Bonaiuti, VP; Seminara, P, 1994) |
| "The SF-767 brain tumors were extremely responsive to BE-4-4-4-4 alone (3 of 8 complete regressions after 2 cycles); however, the growth of the U-87 MG brain tumor was only slightly inhibited by BE-4-4-4-4 treatment." | 1.29 | Effect of 1,19-bis(ethylamino)-5,10,15-triazanonadecane on human tumor xenografts. ( Basu, HS; Casero, RA; Dolan, ME; Feuerstein, BG; Fleig, MJ; Luk, GD; Marton, LJ, 1994) |
| "Human colon cancer (HT29) cell survival was decreased by almost 1 log when treated with 500 microM temozolomide prior to 150 microM BCNU." | 1.29 | Effect of temozolomide and dacarbazine on O6-alkylguanine-DNA alkyltransferase activity and sensitivity of human tumor cells and xenografts to 1,3-bis(2-chloroethyl)-1-nitrosourea. ( Dolan, ME; Mitchell, RB, 1993) |
| "Human colon cancer is resistant to a variety of alkylating agents including the nitrosoureas." | 1.28 | Modulation of nitrosourea resistance in human colon cancer by O6-methylguanine. ( Arce, C; Berger, NA; Gerson, SL; Petzold, SJ; Willson, JK, 1992) |
| "5 degrees C, 3 X 60 min) alone and in combination with polychemotherapy (BCNU) and Ftorafur) was used for the treatment of AMMN-(N-nitrosoacetoxymethyl-methylamine) induced autochthonous colonic carcinomas in Sprague-Dawley rats." | 1.27 | [Effect of local moderate hyperthermia in combination with N-nitroso-1,3-bis-(2-chloroethyl)urea (BCNU) and 5-fluoro-(tetrahydro-2-furyl)uracil (ftorafur) on induced autochthonous colonic cancers in the rat. 3: Polychemotherapy in combination with hyperth ( Biwer, E; Habs, M; Lorenz, M; Schmähl, D, 1984) |
| "Eighty Wistar rats received a colon cancer producing regimen on DMH (40 mg/kg body weight/week, subcutaneously for 10 weeks)." | 1.27 | Combination chemotherapy with 5-fluorouracil (5FU) and 1,3-bis(2-chloro-ethyl)-1-nitrosourea (BCNU) prolongs survival of rats with dimethylhydrazine-induced colon cancer. ( Clark, CG; Cruse, JP; Danzi, M; Lewin, MR, 1983) |
| "The mitomycin C and BCNU were alternated monthly at the start of each FUDR cycle." | 1.27 | Treatment of metastatic colorectal cancer with hepatic artery combination chemotherapy. ( Cohen, AM; Higgins, J; Schaeffer, N, 1986) |
| "The therapy of cancer of the colon still remains unsatisfactory: the rate of remissions could be increased, but survival remains unaltered." | 1.26 | [Current state of therapy for gastrointestinal tumors]. ( Hartmann, D; Obrecht, JP, 1978) |
| "Although advanced gastrointestinal cancer is the most commonplace problem encountered by the medical oncologist, this group of diseases has proved exceedingly resistant to past chemotherapy efforts." | 1.25 | Clinical management of advanced gastrointestinal cancer. ( Moertel, CG, 1975) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 46 (62.16) | 18.7374 |
| 1990's | 21 (28.38) | 18.2507 |
| 2000's | 5 (6.76) | 29.6817 |
| 2010's | 2 (2.70) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Das, D | 1 |
| Preet, R | 1 |
| Mohapatra, P | 1 |
| Satapathy, SR | 1 |
| Kundu, CN | 1 |
| Basak, D | 1 |
| Punganuru, SR | 1 |
| Srivenugopal, KS | 2 |
| Liu, L | 7 |
| Yan, L | 1 |
| Donze, JR | 1 |
| Gerson, SL | 9 |
| Plotnikov, A | 2 |
| Fishman, D | 1 |
| Tichler, T | 2 |
| Korenstein, R | 2 |
| Keisari, Y | 2 |
| Heim, ME | 3 |
| Eberwein, S | 1 |
| Georgi, M | 1 |
| Queisser, W | 1 |
| Biwer, E | 2 |
| Lorenz, M | 3 |
| Habs, M | 5 |
| Schmähl, D | 5 |
| Rubin, J | 1 |
| Schutt, AJ | 1 |
| O'Connell, MJ | 1 |
| Gertz, MA | 1 |
| Moertel, CG | 5 |
| Swoboda, M | 1 |
| Pahlke, W | 1 |
| Edler, L | 1 |
| Bicker, U | 1 |
| Danzi, M | 1 |
| Lewin, MR | 1 |
| Cruse, JP | 1 |
| Clark, CG | 1 |
| Falkson, G | 2 |
| Falkson, HC | 2 |
| Navarra, S | 1 |
| Melita, P | 1 |
| Di Mauro, S | 1 |
| Cowen, DM | 1 |
| Siegerstetter, J | 1 |
| Janik, AC | 1 |
| Double, JA | 1 |
| Giuliani, FC | 1 |
| Zirvi, KA | 2 |
| Kaplan, NO | 1 |
| Goldin, A | 1 |
| Schmitz, R | 2 |
| Hüper, J | 1 |
| Pichlmayr, R | 1 |
| Joss, R | 1 |
| Goldhirsch, A | 1 |
| Tschopp, L | 1 |
| Brunner, K | 1 |
| Reinbold, H | 2 |
| Eisenbrand, G | 1 |
| Bhide, S | 2 |
| Goga-Ionescu, S | 1 |
| Kopper, L | 1 |
| Lapis, K | 1 |
| Csányi, E | 1 |
| Horváth, T | 1 |
| Marangolo, M | 1 |
| Bobola, MS | 1 |
| Berger, MS | 1 |
| Silber, JR | 1 |
| Magull-Seltenreich, A | 1 |
| Zeller, WJ | 1 |
| Franchi, F | 1 |
| Seminara, P | 1 |
| Codacci Pisanelli, G | 1 |
| Guazzugli Bonaiuti, VP | 1 |
| Giovagnorio, F | 1 |
| Gualdi, G | 1 |
| Villa, R | 1 |
| Zaffaroni, N | 1 |
| Orlandi, L | 1 |
| Bearzatto, A | 1 |
| Costa, A | 1 |
| Silvestrini, R | 1 |
| Dolan, ME | 4 |
| Fleig, MJ | 1 |
| Feuerstein, BG | 1 |
| Basu, HS | 1 |
| Luk, GD | 1 |
| Casero, RA | 1 |
| Marton, LJ | 1 |
| Pegg, AE | 1 |
| Moschel, RC | 2 |
| Grindey, GB | 1 |
| Najjar, TA | 1 |
| Slomiany, BL | 1 |
| Zborowska, E | 2 |
| Norton, K | 1 |
| Gordon, NH | 2 |
| Willson, JK | 3 |
| Mitchell, RB | 2 |
| Ewend, MG | 1 |
| Williams, JA | 1 |
| Tabassi, K | 1 |
| Tyler, BM | 1 |
| Babel, KM | 1 |
| Anderson, RC | 1 |
| Pinn, ML | 1 |
| Brat, DJ | 1 |
| Brem, H | 1 |
| Webber, J | 1 |
| Luo, Y | 1 |
| Crilly, R | 1 |
| Fromm, D | 1 |
| Kessel, D | 1 |
| Markowitz, S | 1 |
| Tschmelitsch, J | 1 |
| Barendswaard, E | 1 |
| Williams, C | 1 |
| Yao, TJ | 1 |
| Cohen, AM | 3 |
| Old, LJ | 1 |
| Welt, S | 1 |
| Phillips, WP | 1 |
| Markowitz, SD | 1 |
| Zaidi, NH | 1 |
| Reese, JS | 2 |
| Davis, BM | 3 |
| Belfi, CA | 1 |
| Chatterjee, S | 2 |
| Gosky, DM | 1 |
| Berger, SJ | 1 |
| Berger, NA | 2 |
| Koç, ON | 1 |
| Majczenko, KJ | 1 |
| Taverna, P | 1 |
| Whitacre, CM | 1 |
| Bates, RC | 1 |
| Edwards, NS | 1 |
| Burns, GF | 1 |
| Fisher, DE | 1 |
| Schwartz, S | 1 |
| Woolley, PV | 1 |
| Macdonald, JS | 2 |
| Schein, PS | 2 |
| Drewinko, B | 1 |
| Barlogie, B | 1 |
| Freireich, EJ | 1 |
| Corbett, TH | 1 |
| Griswold, DP | 1 |
| Wolpert, MK | 1 |
| Venditti, JM | 1 |
| Schabel, FM | 2 |
| Hartmann, D | 1 |
| Obrecht, JP | 1 |
| Giles, GR | 1 |
| Lawton, JO | 1 |
| Kisner, D | 1 |
| Carter, SK | 3 |
| Hill, GJ | 1 |
| Johnson, RO | 1 |
| Metter, G | 1 |
| Wilson, WL | 1 |
| Davis, HL | 1 |
| Grage, T | 1 |
| Fletcher, WS | 1 |
| Golomb, FM | 1 |
| Cruz, AB | 1 |
| von Eyben, FE | 1 |
| Larsen, V | 1 |
| Pedersen, H | 1 |
| Wasserman, TH | 1 |
| Slavik, M | 1 |
| Arce, C | 1 |
| Petzold, SJ | 1 |
| Atassi, G | 1 |
| Dumont, P | 1 |
| Gosse, C | 1 |
| Fournier, JP | 1 |
| Gouyette, A | 1 |
| Roger, P | 1 |
| Blöchl, H | 1 |
| Schröder, U | 1 |
| Souhami, R | 1 |
| Peters, W | 1 |
| Schaeffer, N | 1 |
| Higgins, J | 1 |
| Kaufman, SD | 1 |
| Wood, WC | 1 |
| Schaefer, EL | 1 |
| Morimoto, RI | 1 |
| Theodorakis, NG | 1 |
| Seidenfeld, J | 1 |
| Kramer, RA | 1 |
| Zakher, J | 1 |
| Kim, G | 1 |
| Platinskiĭ, LV | 1 |
| Sokolova, VD | 1 |
| Ozhiganov, EL | 1 |
| Marsh, JC | 1 |
| DeConti, RC | 1 |
| Hubbard, SP | 1 |
| Tormey, DC | 1 |
| Gailani, S | 1 |
| Leone, L | 1 |
| McElwain, TJ | 1 |
| van Eden, EB | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase I Trial of 5-Fluoro-2'-Deoxycytidine With Tetrahydrouridine[NCT00359606] | Phase 1 | 58 participants (Actual) | Interventional | 1999-04-30 | Completed | ||
| Phase 0 Trial of [F-18]-5-Fluoro-2'-Deoxycytidine With Tetrahydrouridine[NCT01479348] | Early Phase 1 | 5 participants (Actual) | Interventional | 2011-11-01 | Terminated (stopped due to Slow, insufficient accrual.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Here is the number of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. (NCT01479348)
Timeframe: Date treatment consent signed to date off study, approximately 20 months and 12 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| 1/Intravenous (IV) Tetrahydrouridine (THU) | 2 |
[F-18]-5-fluoro-2'-deoxycytidine (FdCyd) was administered intravenously with administration of tetrahydrouridine (THU) and the frequency and severity of adverse events was observed. A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. Grade 0 is normal, Grade 1 is mild, Grade 2 is moderate, Grade 3 is severe or medically significant but not immediately life-threatening, Grade 4 is life-threatening consequences, and Grade 5 is death related to adverse event. (NCT01479348)
Timeframe: Within 5 days after interventions
| Intervention | adverse events (Number) | |||||
|---|---|---|---|---|---|---|
| Day 1 Adverse Events | Day 2, Grade 2 Hypoalbuminemia | Day 2, Grade 3 Anemia | Day 3 Adverse Events | Day 4 Adverse Events | Day 5 Adverse Events | |
| 1/Intravenous (IV) Tetrahydrouridine (THU) | 0 | 1 | 1 | 0 | 0 | 0 |
Radiation dosimetry was determined based on the first patients. This involved making region of interest measurements on the scan for each major organ and measuring the uptake. Using standard dosimetry software this is converted into mSv/MBq, a standard measure of dosimetry. The software is known as Organ Level INternal Dose Assessment/EXponential Modeling (OLINDA) and is commonly used to generate this kind of data. (NCT01479348)
Timeframe: 1 year
| Intervention | mSv/MBq (Mean) | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Adrenals | Brain | Breasts | Gallbladder wall | Lower large intestine wall | Small intestine | Stomach wall | Upper large intestine wall | Heart wall | Kidneys | Liver | Lungs | Muscle | Ovaries | Pancreas | Red marrow | Osteogenic cells | Skin | Spleen | Testes | Thymus | Thyroid | Urinary bladder wall | Uterus | |
| 1/Intravenous (IV) Tetrahydrouridine (THU) | 1.83 | 8.17 | 1.03 | 4.05 | 2.52 | 2.13 | 1.90 | 2.04 | 1.10 | 5.26 | 6.02 | 1.82 | 1.16 | 1.57 | 1.63 | 1.14 | 1.71 | 8.65 | 1.69 | 1.03 | 1.12 | 8.23 | 7.96 | 1.63 |
Participants were scanned by positron emission tomography (PET) and lesions were measured at 4 time points after injection. (NCT01479348)
Timeframe: 9 minutes, 32 minutes, 56 minutes and 2 hours after injection
| Intervention | TBR ratio (Number) | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pt 1 L. Parotid adenosquam. cell ca at 9 min | Pt 1 L. Parotid adenosquam. cell ca at 32 min | Pt 1 L. Parotid adenosquam. cell ca at 56 min | Pt 1 L. Parotid adenosquam. cell ca at 2 hrs | Pt 2 R. Parapharyngeal Spindle Cell Ca at 9 min | Pt 2 R. Parapharyngeal Spindle Cell Ca at 32 min | Pt 2 R. Parapharyngeal Spindle Cell Ca at 56 min | Pt 2 R. Parapharyngeal Spindle Cell Ca at 2 hrs | Pt 3 Non-small Cell Lung Ca at 9 min | Pt 3 Non-small Cell Lung Ca at 32 min | Pt 3 Non-small Cell Lung Ca at 56 min | Pt 3 Non-small Cell Lung Ca at 2 hrs | Pt 4 Non-small Cell Lung Ca at 9 min | Pt 4 Non-small Cell Lung Ca at 32 min | Pt 4 Non-small Cell Lung Ca at 56 min | Pt 4 Non-small Cell Lung Ca at 2 hrs | Pt 5 Hepatocellular Ca at 9 min | Pt 5 Hepatocellular Ca at 32 min | Pt 5 Hepatocellular Ca at 56 min | Pt 5 Hepatocellular Ca at 2 hrs | |
| 1/Intravenous (IV) Tetrahydrouridine (THU) | 1.4 | 1.5 | 1.5 | 1.6 | 1.9 | 1.7 | 1.7 | 1.6 | 1.4 | 1.4 | 1.5 | 1.7 | 2.4 | 2.1 | 1.6 | 2.0 | NA | NA | NA | NA |
8 reviews available for carmustine and Cancer of Colon
| Article | Year |
|---|---|
Chemotherapy in alimentary tract malignomas.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Carmustine; Colonic Neoplasms; Cytarabine; Doxor | 1981 |
Chemotherapy of colorectal carcinoma.
Topics: Administration, Oral; Antineoplastic Agents; Carmustine; Colonic Neoplasms; Drug Administration Sche | 1976 |
Nitrosoureas: a review of experimental antitumor activity.
Topics: Animals; Carmustine; Colonic Neoplasms; Drug Evaluation, Preclinical; Drug Resistance; Drug Therapy, | 1976 |
Current protocol approaches in large bowel cancer.
Topics: Antineoplastic Agents; Carmustine; Clinical Trials as Topic; Colonic Neoplasms; Dacarbazine; Drug Th | 1976 |
Clinical comparison of the nitrosoureas.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Breast Neoplasms; Carmustine; Chemical Phenomena; C | 1975 |
High dose chemotherapy in solid tumours in adults.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marr | 1986 |
[Chemotherapy of cancer of the large intestine].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Colonic Neoplasms | 1985 |
Chemotherapy in colorectal cancer.
Topics: Carmustine; Chlorambucil; Colonic Neoplasms; Cyclophosphamide; Drug Therapy, Combination; Fluorourac | 1973 |
6 trials available for carmustine and Cancer of Colon
| Article | Year |
|---|---|
Fluorouracil, imidazole carboxamide dimethyl triazeno, vincristine, and bis-chloroethyl nitrosourea (FIVB) in colon cancer.
Topics: Antineoplastic Agents; Carmustine; Clinical Trials as Topic; Colonic Neoplasms; Dacarbazine; Drug Th | 1981 |
Enhanced antitumor activity of combination radioimmunotherapy (131I-labeled monoclonal antibody A33) with chemotherapy (fluorouracil).
Topics: Animals; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antigens, Neoplasm; Antimetabolites, A | 1997 |
Chemotherapy of large intestinal carcinoma. Current results and future prospects.
Topics: Administration, Oral; Antineoplastic Agents; Carmustine; Clinical Trials as Topic; Colonic Neoplasms | 1975 |
Current protocol approaches in large bowel cancer.
Topics: Antineoplastic Agents; Carmustine; Clinical Trials as Topic; Colonic Neoplasms; Dacarbazine; Drug Th | 1976 |
Treatment of Hodgkin's disease and other cancers with 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU; NSC-409962).
Topics: Adenocarcinoma; Adenoma, Islet Cell; Adolescent; Adrenal Gland Neoplasms; Adult; Alkylating Agents; | 1971 |
Fluorouracil, imidazole carboxamide dimethyl triazeno, vincristine, and bis-chloroethyl nitrosourea in colon cancer.
Topics: Alopecia; Amides; Antineoplastic Agents; Carmustine; Clinical Trials as Topic; Colonic Neoplasms; Dr | 1974 |
61 other studies available for carmustine and Cancer of Colon
| Article | Year |
|---|---|
1,3-Bis(2-chloroethyl)-1-nitrosourea enhances the inhibitory effect of resveratrol on 5-fluorouracil sensitive/resistant colon cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Carmustine | 2013 |
Piperlongumine exerts cytotoxic effects against cancer cells with mutant p53 proteins at least in part by restoring the biological functions of the tumor suppressor.
Topics: Animals; Carmustine; Colonic Neoplasms; Dioxolanes; DNA-Binding Proteins; Doxorubicin; Drug Resistan | 2016 |
Blockage of abasic site repair enhances antitumor efficacy of 1,3-bis-(2-chloroethyl)-1-nitrosourea in colon tumor xenografts.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Carmustine; Cell Division; Coloni | 2003 |
Low electric field enhanced chemotherapy can cure mice with CT-26 colon carcinoma and induce anti-tumour immunity.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; | 2004 |
Involvement of the immune response in the cure of metastatic murine CT-26 colon carcinoma by low electric field-enhanced chemotherapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Carmustine; Cell Line, Tumor; Colonic Neoplasms; Flow Cy | 2005 |
Palliative therapy of pelvic tumors by intra-arterial infusion of cytotoxic drugs.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Colonic Neoplasms; Doxorubicin; Fe | 1983 |
[Effect of local moderate hyperthermia in combination with N-nitroso-1,3-bis-(2-chloroethyl)urea (BCNU) and 5-fluoro-(tetrahydro-2-furyl)uracil (ftorafur) on induced autochthonous colonic cancers in the rat. 3: Polychemotherapy in combination with hyperth
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinogens; Carmustine; Colon; Colonic Neo | 1984 |
[Effect of local moderate hyperthermia in combination with chemotherapy by N-nitroso-1,3-bis-(2-chloroethyl)urea (BCNU) on the descending colon of the rat with transplanted Yoshida sarcoma. 2. Monochemotherapy in combination with subsequent hyperthermia a
Topics: Animals; Carmustine; Colonic Neoplasms; Combined Modality Therapy; Hyperthermia, Induced; Male; Neop | 1984 |
A phase II study of the combination, 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) and N-(phosphonacetyl)-L-aspartate (PALA), in patients with advanced large bowel cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Carmusti | 1984 |
Treatment of autochthonous rat colonic adenocarcinomas with a thioether-lysophospholipid derivative in mono- and combination chemotherapy.
Topics: Adenocarcinoma; Administration, Oral; Animals; Antineoplastic Agents; Antineoplastic Combined Chemot | 1984 |
Combination chemotherapy with 5-fluorouracil (5FU) and 1,3-bis(2-chloro-ethyl)-1-nitrosourea (BCNU) prolongs survival of rats with dimethylhydrazine-induced colon cancer.
Topics: 1,2-Dimethylhydrazine; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinogens; Carmust | 1983 |
[Effect of moderate local hyperthermia in combination with chemotherapy with cyclophosphamide or N-nitroso- 1,3-bis(2-chloroethyl)urea(BCNU) on Yoshida sarcoma implanted in the descending colon of rats. 1. Repeated hyperthermia within 8 days and combinati
Topics: Animals; Carmustine; Colonic Neoplasms; Cyclophosphamide; Hot Temperature; Male; Rats; Rats, Inbred | 1983 |
[Immunotherapy in the treatment of colorectal cancers in the aged].
Topics: Aged; Aging; BCG Vaccine; Carmustine; Colonic Neoplasms; Female; Fluorouracil; Humans; Male; Middle | 1982 |
The assessment of response of murine transplantable colon tumors to combination chemotherapy.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Carmustine; Cell Line; Colonic Neoplasms; Dimethylhy | 1982 |
Chemotherapy of human colorectal tumor xenografts in athymic mice with clinically active drugs: 5-fluorouracil and 1-3-bis-(-2-chloroethyl)-1-nitrosourea (BCNU). Comparison with doxorubicin derivatives: 4'deoxydoxorubicin and 4'-O-methyldoxorubicin.
Topics: Adenocarcinoma; Animals; Carmustine; Colonic Neoplasms; Doxorubicin; Fluorouracil; Humans; Mice; Mic | 1981 |
Studies in an animal model on the effectiveness of adjuvant chemotherapy with 5-FU and BCNU in cases of colorectal adenocarcinoma.
Topics: Adenocarcinoma; Animals; Carmustine; Colonic Neoplasms; Drug Therapy, Combination; Female; Fluoroura | 1981 |
[Gastrointestinal tumors. Prognostic factors and chemotherapy of today].
Topics: Carmustine; Colonic Neoplasms; Doxorubicin; Female; Fluorouracil; Gastrointestinal Neoplasms; Humans | 1981 |
Antitumor activity of new nitrosoureas on Yoshida sarcoma ascites cells implanted into the colon wall of rats.
Topics: Animals; Antineoplastic Agents; Carmustine; Colonic Neoplasms; Male; Neoplasm Transplantation; Nitro | 1981 |
Effect of a new bifunctional nitrosoureido derivative on human colorectal tumor xenografts.
Topics: Animals; Antineoplastic Agents; Carmustine; Cell Division; Cell Line; Colonic Neoplasms; Humans; Mic | 1981 |
[Evaluation of the 1st trials of adjuvant treatment. Future prospects].
Topics: Adult; Aged; Antineoplastic Agents; Carmustine; Colonic Neoplasms; Female; Fluorouracil; Humans; Mal | 1980 |
Contribution of O6-methylguanine-DNA methyltransferase to resistance to 1,3-(2-chloroethyl)-1-nitrosourea in human brain tumor-derived cell lines.
Topics: Brain Neoplasms; Carmustine; Cell Adhesion; Colonic Neoplasms; Culture Media; Drug Resistance; Drug | 1995 |
Sensitization of human colon tumour cell lines to carmustine by depletion of O6-alkylguanine-DNA alkyltransferase.
Topics: Carmustine; Colonic Neoplasms; Drug Resistance; Drug Screening Assays, Antitumor; Guanine; Humans; M | 1995 |
Elevated doses of carmustine and mitomycin C, with lonidamine enhancement and autologous bone marrow transplantation in the treatment of advanced colorectal cancer: results from a pilot study.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplant | 1994 |
In vitro effect of lonidamine on the cytotoxicity of mitomycin C and BCNU in human colon adenocarcinoma cells.
Topics: Adenocarcinoma; Antineoplastic Agents; Carmustine; Cell Cycle; Cell Survival; Colonic Neoplasms; Dos | 1994 |
Effect of 1,19-bis(ethylamino)-5,10,15-triazanonadecane on human tumor xenografts.
Topics: Animals; Body Weight; Brain Neoplasms; Carmustine; Cell Division; Colonic Neoplasms; Drug Screening | 1994 |
Effect of O6-benzylguanine on the sensitivity of human colon tumor xenografts to 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU).
Topics: Animals; Carmustine; Cell Division; Colonic Neoplasms; Drug Synergism; Female; Guanine; Humans; Meth | 1993 |
Sensitivity of human colon tumor metastases to anticancer drugs in athymic (nude) mice.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Carmustine; Colonic Neoplasms; Doxorubicin; Female; | 1993 |
Synergistic efficacy of O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) in a human colon cancer xenograft completely resistant to BCNU alone.
Topics: Alkyl and Aryl Transferases; Animals; Antineoplastic Combined Chemotherapy Protocols; Body Weight; C | 1993 |
Effect of temozolomide and dacarbazine on O6-alkylguanine-DNA alkyltransferase activity and sensitivity of human tumor cells and xenografts to 1,3-bis(2-chloroethyl)-1-nitrosourea.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Colonic Neoplasms; Dacarbazine; | 1993 |
Local delivery of chemotherapy and concurrent external beam radiotherapy prolongs survival in metastatic brain tumor models.
Topics: Animals; Antineoplastic Agents; Brain; Brain Neoplasms; Camptothecin; Carboplatin; Carcinoma; Carcin | 1996 |
An apoptotic response to photodynamic therapy with endogenous protoporphyrin in vivo.
Topics: Animals; Apoptosis; Carmustine; Colonic Neoplasms; DNA Fragmentation; Doxorubicin; Etoposide; Mice; | 1996 |
Mismatch repair mutations override alkyltransferase in conferring resistance to temozolomide but not to 1,3-bis(2-chloroethyl)nitrosourea.
Topics: Antineoplastic Agents, Alkylating; Carmustine; Colonic Neoplasms; Dacarbazine; DNA Adducts; DNA Dama | 1996 |
O6-methylguanine-DNA methyltransferase (MGMT) transfectants of a 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU)-sensitive colon cancer cell line selectively repopulate heterogenous MGMT+/MGMT- xenografts after BCNU and O6-benzylguanine plus BCNU.
Topics: Animals; Antineoplastic Agents; Carmustine; Colonic Neoplasms; DNA Repair; Drug Resistance, Neoplasm | 1997 |
Simultaneous protection of G156A methylguanine DNA methyltransferase gene-transduced hematopoietic progenitors and sensitization of tumor cells using O6-benzylguanine and temozolomide.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Carmustine; Colonic Neoplasms; Da | 1999 |
Increased sensitivity of human colon cancer cells to DNA cross-linking agents after GRP78 up-regulation.
Topics: 6-Aminonicotinamide; Blotting, Western; Carmustine; Carrier Proteins; Cell Survival; Cisplatin; Colo | 1999 |
DeltaMGMT-transduced bone marrow infusion increases tolerance to O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea and allows intensive therapy of 1,3-bis(2-chloroethyl)-1-nitrosourea-resistant human colon cancer xenografts.
Topics: Animals; Antineoplastic Agents, Alkylating; Bone Marrow Transplantation; Carmustine; Cell Division; | 1999 |
Pharmacologic disruption of base excision repair sensitizes mismatch repair-deficient and -proficient colon cancer cells to methylating agents.
Topics: Antineoplastic Agents, Alkylating; Carmustine; Cell Cycle; Colonic Neoplasms; Dacarbazine; DNA Repai | 1999 |
A CD44 survival pathway triggers chemoresistance via lyn kinase and phosphoinositide 3-kinase/Akt in colon carcinoma cells.
Topics: Antineoplastic Agents, Alkylating; Carmustine; Cell Survival; Colonic Neoplasms; Drug Resistance, Ne | 2001 |
Chemotherapy-induced O(6)-benzylguanine-resistant alkyltransferase mutations in mismatch-deficient colon cancer.
Topics: Adaptor Proteins, Signal Transducing; Alkyl and Aryl Transferases; Animals; Antineoplastic Agents, A | 2002 |
Clinical management of advanced gastrointestinal cancer.
Topics: Adenoma, Islet Cell; Carcinoma, Hepatocellular; Carmustine; Colonic Neoplasms; Cytarabine; Drug Ther | 1975 |
Walter Hubert lecture Chemotherapy of upper gastrointestinal carcinoma.
Topics: Adenoma, Islet Cell; Antineoplastic Agents; Carcinoid Tumor; Carcinoma, Hepatocellular; Carcinoma, S | 1976 |
Response of exponentially growing, stationary-phase, and synchronized cultured human colon carcinoma cells to treatment with nitrosourea derivatives.
Topics: Carmustine; Cell Cycle; Cell Division; Cell Survival; Cells, Cultured; Colonic Neoplasms; Dose-Respo | 1979 |
Design and evaluation of combination chemotherapy trials in experimental animal tumor systems.
Topics: Animals; Antineoplastic Agents; Carmustine; Cisplatin; Colonic Neoplasms; Drug Evaluation, Preclinic | 1979 |
Antitumor activity of 1,3-bis-(2-chloroethyl)-1-nitrosourea (BCNU) and 1-(2-chloroethyl)-3-(4-methyl-cyclohexyl)-1-nitrosourea (MeCCNU) on Yoshida sarcoma ascites cells implanted into the colon wall of rats.
Topics: Animals; Body Weight; Carmustine; Colonic Neoplasms; Cyclophosphamide; Male; Nitrosourea Compounds; | 1979 |
[Current state of therapy for gastrointestinal tumors].
Topics: Carmustine; Colonic Neoplasms; Drug Therapy, Combination; Fluorouracil; Gastrointestinal Neoplasms; | 1978 |
Chemotherapy for known residual disease after resection of gastric and colorectal cancer.
Topics: Carcinoembryonic Antigen; Carmustine; Colonic Neoplasms; Fluorouracil; Gastrointestinal Neoplasms; H | 1978 |
Multimodal surgical adjuvant therapy for a broad spectrum of tumors in humans.?
Topics: Adult; Altretamine; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Carmustine; Colonic Neo | 1976 |
Gastrointestinal cancer. Treatment with fluorouracil-nitrosourea combinations.
Topics: Carmustine; Colonic Neoplasms; Drug Therapy, Combination; Female; Fluorouracil; Gastrointestinal Neo | 1976 |
5-Fluorouracil (NSC-19893), DTIC (NSC-45388), BCNU (NSC-409962), and vincristine (NSC-67574) in advanced colorectal carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Carmustine; Colonic Neoplasms; Dacarbazine; Drug Therapy, Combin | 1976 |
Editorial: Large-bowel cancer-The current status of treatment.
Topics: Adjuvants, Immunologic; BCG Vaccine; Carmustine; Colonic Neoplasms; Doxorubicin; Drug Therapy, Combi | 1976 |
Editorial: Large-bowel cancer-The current status of treatment.
Topics: Adjuvants, Immunologic; BCG Vaccine; Carmustine; Colonic Neoplasms; Doxorubicin; Drug Therapy, Combi | 1976 |
Editorial: Large-bowel cancer-The current status of treatment.
Topics: Adjuvants, Immunologic; BCG Vaccine; Carmustine; Colonic Neoplasms; Doxorubicin; Drug Therapy, Combi | 1976 |
Editorial: Large-bowel cancer-The current status of treatment.
Topics: Adjuvants, Immunologic; BCG Vaccine; Carmustine; Colonic Neoplasms; Doxorubicin; Drug Therapy, Combi | 1976 |
Formation and disappearance of DNA interstrand cross-links in human colon tumor cell lines with different levels of resistance to chlorozotocin.
Topics: Antineoplastic Agents; Carmustine; Colonic Neoplasms; Cross-Linking Reagents; DNA, Neoplasm; Drug Re | 1992 |
Modulation of nitrosourea resistance in human colon cancer by O6-methylguanine.
Topics: Carmustine; Colonic Neoplasms; DNA Repair; Drug Resistance; Guanine; Humans; Methyltransferases; O(6 | 1992 |
Effect of O6-benzylguanine on the sensitivity of human tumor xenografts to 1,3-bis(2-chloroethyl)-1-nitrosourea and on DNA interstrand cross-link formation.
Topics: Animals; Carmustine; Colonic Neoplasms; DNA; DNA, Neoplasm; DNA, Single-Stranded; Drug Resistance; D | 1992 |
Characterization of the anti-tumour activity against solid tumours of a new nitrosoureido sugar: Cy 233.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Carmustine; Colonic Neoplasms; Dose-Response Relatio | 1989 |
Human-alpha-interferon on xenotransplanted human colonic adenocarcinomas in nude mice.
Topics: Adenocarcinoma; Animals; Carmustine; Colonic Neoplasms; Female; Fluorouracil; Humans; Interferon Typ | 1989 |
Treatment of metastatic colorectal cancer with hepatic artery combination chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Colonic Neoplasms; Fluorouracil; Follow- | 1986 |
Treatment of colorectal cancer hepatic metastases by hepatic artery chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Colonic Neoplasms; Floxuridine; Fluorour | 1985 |
Chemical specificity for induction of stress response genes by DNA-damaging drugs in human adenocarcinoma cells.
Topics: Adenocarcinoma; Antineoplastic Agents; Carmustine; Cell Line; Colonic Neoplasms; DNA Damage; Genes; | 1988 |
Role of the glutathione redox cycle in acquired and de novo multidrug resistance.
Topics: Animals; Carmustine; Colonic Neoplasms; Doxorubicin; Drug Resistance; Glutathione; Glutathione Perox | 1988 |
Phase II evaluation of BCNU and 5-FU in gastrointestinal carcinomas.
Topics: Adenocarcinoma; Administration, Oral; Carmustine; Colonic Neoplasms; Diarrhea; Fluorouracil; Hematoc | 1974 |
Therapy of advanced gastrointestinal cancer with the nitrosoureas.
Topics: Adenocarcinoma; Antineoplastic Agents; Bone Marrow Diseases; Carmustine; Colonic Neoplasms; Cyclohex | 1973 |